Guggenheim Downgrades Dermira (DERM) to Neutral Following Acquisition
Tweet
Share
E-mailGet Alerts DERM Hot Sheet
Price: $6.81 +2.25%
Rating Summary:
12 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 5 | New: 8
Rating Summary:
12 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 5 | New: 8
Join SI Premium – FREE
Guggenheim analyst Seamus Fernandez downgraded Dermira (NASDAQ: DERM) from Buy to Neutral with a price target of $18.75.
For an analyst ratings summary and ratings history on Dermira click here. For more ratings news on Dermira click here.
Shares of Dermira closed at $18.95 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $55 at Guggenheim
- RBC Capital Downgrades Temple & Webster Group Ltd (TPW:AU) to Sector Perform
- Morgan Stanley Downgrades Liberty LiLAC (LILA) to Underweight
Create E-mail Alert Related Categories
DowngradesRelated Entities
GuggenheimSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
